Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the USA: 2005-09

被引:42
作者
Kimball, A. B. [1 ,2 ]
Schenfeld, J. [3 ]
Accortt, N. A. [3 ]
Anthony, M. S. [3 ]
Rothman, K. J. [4 ]
Pariser, D. [5 ]
机构
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Amgen Inc, Ctr Observat Res, Thousand Oaks, CA 91320 USA
[4] RTI Int, Res Triangle Pk, NC USA
[5] Virginia Clin Res Inc, Norfolk, VA USA
关键词
NECROSIS FACTOR THERAPY; SERIOUS INFECTIONS; RISK; ARTHRITIS; COHORT; LYMPHOMA;
D O I
10.1111/bjd.12744
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Rates of malignancies and hospitalized infectious events (HIEs) among psoriasis patients are higher than in the general population, but it is unclear if higher rates are associated with the underlying inflammatory state, treatments or both. Objectives To assess the incidence of malignancies and HIEs in a healthy US population, a psoriasis population, and four treated psoriasis populations. Methods Using a US claims database, we identified a general population, a psoriasis cohort, and four treatment cohorts [non-biologic systemics, etanercept, other TNF blockers (adalimumab, infliximab) and phototherapy] to assess the incidence of lymphomas, nonmelanoma skin cancer (NMSC), all malignancies (excluding NMSC), and HIEs, standardized for age and sex. Results Among 40 987 patients with psoriasis, 11% were prescribed non-biologics, 15% etanercept, 6% other TNF blockers and 11% phototherapy. For all cancers, the psoriasis population rate (114/10 000 person-years) was 20% greater than the rate found in the general population (95/10 000 person-years). For NMSC, the psoriasis population rate (129/10 000 person-years) was 65% greater than the general population rate (78/10 000 person-years). The incidence rate for each treatment modality was lower than the overall psoriasis cohort, except for phototherapy. There was little difference in the rates of lymphomas. NMSC rates were higher among patients treated with phototherapy. HIE rates ranged from 165/10 000 person-years for the phototherapy group to 262/10 000 person-years for the other anti-TNF group. Conclusions Patients with psoriasis appear to have higher rates of malignancy and HIE than the general population, with little difference in rates between the treatment methods, except for a higher rate of cancer among those receiving phototherapy. What's already known about this topic? Some evidence shows elevated rates of malignancies and serious infections among psoriasis patients in general but also for those on therapeutic regimens. What does this study add? This study provides evidence that the elevated rates of malignancy and serious infections found in psoriasis patients may be due to biological reasons other than specific treatment modalities. © 2013 British Association of Dermatologists.
引用
收藏
页码:366 / 373
页数:8
相关论文
共 21 条
  • [11] The benefit/risk profile of TNF-blocking agents: Findings of a consensus panel
    Hochberg, MC
    Lebwohl, MG
    Plevy, SE
    Hobbs, KF
    Yocum, DE
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2005, 34 (06) : 819 - 836
  • [12] The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004
    Kurd, Shanu Kohli
    Gelfand, Joel M.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (02) : 218 - 224
  • [13] Le Blay P, 2012, CLIN EXP RHEUMATOL, V30, P756
  • [14] Margolis D, 2001, ARCH DERMATOL, V137, P778
  • [15] Guidelines of care for the management of psoriasis and psoriatic arthritis - Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics
    Menter, Alan
    Gottlieb, Alice
    Feldman, Steven R.
    Van Voorhees, Abby S.
    Leonardi, Craig L.
    Gordon, Kenneth B.
    Lebwohl, Mark
    Koo, John Y. M.
    Elmets, Craig A.
    Korman, Neil J.
    Beutner, Karl R.
    Bhushan, Reva
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (05) : 826 - 850
  • [16] National Institute of Health, PSORIASIS
  • [17] National Psoriasis Foundation, TREAT PSOR
  • [18] Treatments for psoriasis and the risk of malignancy
    Patel, Rita V.
    Clark, Lily N.
    Lebwohl, Mark
    Weinberg, Jeffrey M.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 60 (06) : 1001 - 1017
  • [19] Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study
    Paul, CF
    Ho, VC
    McGeown, C
    Christophers, E
    Schmidtmann, B
    Guillaume, JC
    Lamarque, V
    Dubertret, L
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 120 (02) : 211 - 216
  • [20] Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction
    Stern, RS
    Nijsten, T
    Feldman, SR
    Margolis, DJ
    Rolstad, T
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, 2004, 9 (02) : 136 - 139